NXY-059 Centaur

Current Opinion in Investigational Drugs

Volumn 3, Issue 12, 2002, Pages 1758-1762

  Lapchak, Paul A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISUFENTON SODIUM; FIBRINOLYTIC AGENT; FREE RADICAL; N TERT BUTYL ALPHA PHENYLNITRONE; NY 059; PLACEBO; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DOSE KIDNEY FUNCTION RELATION; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG INDICATION; DRUG MARKETING; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG TOXICITY; HUMAN; KIDNEY DYSFUNCTION; NEUROPROTECTION; NONHUMAN; REPERFUSION INJURY; REVIEW; SIDE EFFECT; STROKE; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZENESULFONATES; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; DRUG INDUSTRY; HUMANS; NITROGEN OXIDES;

EID: 0037002411     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. 180191 Potential of spin traps as stroke drugs confirmed in academic study. Emerging Pharmaceuticals 1995 4 7 8-9
2. 187281 AB Astra, Centaur Phamaceuticals Inc. In Vivo 1995 13 7 63
3. 189150 Centaur wins grant to develop nitrone anti-oxidants for Gehrig's disease. Emerging Pharmaceuticals 1995 4 10 P1
4. 216496 Characterization of the radical trapping activity of a novel series of cyclic nitrone spin traps. Thomas CE, Ohlweiler DF, Carr AA, Nieduzak TR, Hay DA, Adams G, Vaz R, Bernotas RC J Biol Chem 1996 271 6 3097-3104
5. 227795 Lundbeck/Centaur Parkinson's deal. Scrip 1996 2187 11
6. 314472 United Kingdom Pharmaceuticals: Zeneca. Merrill Lynch Capital Markets 1999 February 03
7. 320599 Centaur Product Development Programs. Centaur Pharmaceuticals Inc Company World Wide Website 1999 April 08
8. 336599 Pharmaceuticals Europe: AstraZeneca. Lehman Brothers Inc 1999 March 30
9. 344683 Society for Neuroscience 29th Annual Meeting (Part II), Miami Beach, FL, USA. Kibble A, Nicholls R IDDB Meeting Report
10. 347064 Annual Report 1997. H Lundbeck. Company World Wide Website 1999 November 10 Disclosed that the collaboration with Centaur Pharmaceuticals for Parkinson's disease products had ended in March 1998
11. 364859 Centaur Pharmaceuticals announces first quarter 2000 financial results. Centaur Pharmaceuticals Inc Press Release 2000 May 02
12. 368539 Centaur Pharmaceuticals announces presentation of results from NXY-059 phase IIa stroke trial at the 10th European Stroke Congress. Centaur Pharmaceuticals Inc Press Release 2000 May 26 NXY-059 was safe in stroke patients at a dose that exceeded the highest dose tested in the rat focal stroke model.
13. 374500 AstraZeneca - Nexium: A product or dose effect? Deutsche Banc Alex Brown 2000 June 01 1-12
14. 376653 Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. Kuroda S, Tsuchidate R, Smith M-L, Maples KR, Siesjo BK J Cereb Blood Flow Metab 1999 19 7 778-787
15. 377656 AstraZeneca R&D pipeline: NCEs. AstraZeneca plc. Company World Wide Website 2000 August 01
16. 383742 Pharmaceutical Models: Europe. Merrill Lynch Capital Markets 2000 September 25
17. 385400 Centaur Pharmaceuticals announces initiation of the first US stroke clinical trial with NXY-059. Centaur Pharmaceuticals Inc Press Release 2000 October 11
18. 387961 Centaur Pharmaceuticals announces third quarter 2000 financial results. Centaur Pharmaceuticals Inc Press Release 2000 October 31
19. 404023 Efficacy of disodium 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (NXY-059), a free radical trapping agent, in a rat model of hemorrhagic stroke. Peeling J, Del Bigio MR, Corbett D, Green AR, Jackson DM Neuropharmacology 2001 40 3 433-439
20. 409176 Centaur Pharmaceuticals announces proof of concept efficacy in phase IIa clinical trials with CPI-1189 in Parkinson's and AIDS dementia. Centaur Pharmaceuticals Inc Press Release 2001 May 15
21. 428729 NXY-059, a novel free radical trapping compound, reduced cortical infarction after permanent focal cerebral ischemia in the rat. Zhao Z, Cheng M, Maples KR, Ma JY, Buchan AM Brain Res 2001 909 1-2 46-50
22. 428734 Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke. Lees KR, Sharma AK, Barer D, Ford GA, Kostulas V, Cheng Y-F, Odergren T Stroke 2001 32 3 675-680
23. 428735 NXY-059, a free radical trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Marshall JW, Duffin KJ, Green AR, Ridley RM Stroke 2001 32 1 190-198
24. 429697 AstraZeneca: The Pipeline's coming. Culverwell J, Barnes N, Maxwell C, Aldersley J Merrill Lynch Capital Markets 2001 February 01
25. 429700 AstraZeneca: Bright light, long tunnel. Baum A, Moore D, Mann P, Forero M, Recordati A Morgan Stanley Dean Witter 2001 October 25
26. 431673 AstraZeneca R&D pipeline. AstraZeneca Plc Company Presentation 2001 December 03
27. 442353 Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat: Studies on dose, plasma concentrations and therapeutic time window. Sydserff SG, Borelli AR, Green AR, Cross AJ Br J Pharmacol 2002 135 1 103-112
28. 458944 Mechanisms of secondary brain injury. Siesjo BK, Siesjo P Eur J Anaesthesiol 1996 13 3 247-268
29. 458946 Effects of the spin trap agent disodium-[tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit large clot embolic stroke model: Combination studies with tissue plasminogen activator. Lapchak PA, Araujo DM, Song D, Wei J, Purdy R, Zivin JA Stroke 2002 33 6 1665-1670
30. 458947 Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: Combination studies with the thrombolytic tissue plasminogen activator. Lapchak PA, Araujo DM, Song D, Wei J, Zivin JA Stroke 2002 33 5 1411-1415
31. 458948 Comparison of the radical trapping ability of PBN, S-PBN and NXY-059. Maples KR, Ma J, Zhang YK Free Radic Res Commun 2001 34 4 417-426
32. 458951 Effect of NXY-059 on secondary mitochondrial dysfunction after transient focal ischemia: Comparison with cyclosporin A. Yoshimoto T, Kristian T, Hu B, Ouyang YB, Siesjo B Brain Res 2002 932 1-2 99-109
33. 459084 NXY-059, the first nitrone being developed for stroke, is safe and well tolerated in young and elderly healthy volunteers. Edenius C, Strid S, Breitholtz-Emanuelsson A, Dalin L, Jerling M, Fransson B Cerebrovasc Dis 1999 9 Abs 102
34. 459440 AstraZeneca R&D pipeline: NCEs 25 July 2002. AstraZeneca plc Company World Wide Web Site 2002 July 25
35. 469329 Annual Business Review press release: AstraZeneca reports significant progress across its promising research and development portfolio. AstraZeneca Plc Press Release 2002 November 07
36. 469330 AstraZeneca's Annual Business Review 2002 Analyst presentation. AstraZeneca Plc Company Presentation 2002 November 07
37. 469976 Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke. Strid S, Borga O, Edenius C, Jostell KG, Odergren T, Weil A Eur J Clin Pharmacol 2002 58 6 409-415